Research Radartracking 4 published studies · 1 human · 2 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Uterine Carcinosarcoma

Auto-discovered from research; not yet curated.

Auto-added · review pending
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceHuman trial / meta-analysisReported positive
1 published studies that name Uterine Carcinosarcoma1 human studies (trial, observational, or meta-analysis)317 source documents in the Uterine Carcinosarcoma corpus
Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Treatment map: Uterine Carcinosarcoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

3
Interventions
0
Standard of care
3
Tested in people
0
Lab / animal
0
Named in lit.
2
Classes
Standard of care (0) Guideline option (0) Tested in people (3) Lab / animal only (0) Named in the literature (0)

Tested in people, by trial phase: Phase III ×3

Investigational & adjunct compounds — detail (3)

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Living document — last change June 8, 2026: New cancer type added.

Overview

Uterine Carcinosarcoma is tracked here from the published studies that mention it. This page shows the research evidence collected so far — it is not a curated clinical overview.

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
1
Meta-analysis
7
Systematic review
4
Randomized trial
1
Clinical trial
24
Observational
4
Case report
56
Review
220
Preclinical
0
Other
0

Evidence on specific compounds

How the published studies grade individual drugs, supplements, and other agents in Uterine Carcinosarcoma — each rated by how strong the evidence is, not a recommendation.

What recent studies report in Uterine Carcinosarcoma

These are reviewed studies whose abstracts concern Uterine Carcinosarcoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Uterine Carcinosarcoma. Most are early lab, animal, or small human studies, and findings often conflict.

1 study1 humanTrial (1)

Tracking 1 published study of Uterine Carcinosarcoma: 1 in humans.

Reported direction across studies: 1 positive.

These counts summarize what the studies reported; they are not a measure of whether anything works for Uterine Carcinosarcoma.

Compounds with studies mentioning Uterine Carcinosarcoma

Carboplatin (1)Paclitaxel (1)Ifosfamide (1)
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 536

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 2022 · randomized phase III trial

CarboplatinPaclitaxelIfosfamideuterine carcinosarcomaovarian carcinosarcoma

This randomized phase III study compared paclitaxel plus carboplatin with paclitaxel plus ifosfamide in adults with uterine or ovarian carcinosarcoma. In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to the ifosfamide regimen and had longer median overall survival and progression-free survival. Toxicities were broadly similar, although some side effects differed between the two groups.

Reported effects: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 · HR 0.87 [0.7–1.075], p P < .01 for noninferiority, P > .1 for superiority, n=449 · +4 more

Studied with: carboplatin, ifosfamide.

Key findings
  • In uterine carcinosarcoma, paclitaxel plus carboplatin was not inferior to paclitaxel plus ifosfamide for overall survival.
  • Median overall survival was 37 versus 29 months in uterine carcinosarcoma.
  • Median progression-free survival was 16 versus 12 months in uterine carcinosarcoma.
  • Toxicities were similar overall, with more hematologic toxicity in the paclitaxel-carboplatin arm and more confusion and genitourinary hemorrhage in the paclitaxel-ifosfamide arm.
  • In ovarian carcinosarcoma, paclitaxel plus carboplatin had numerically longer survival outcomes, but the differences were not statistically significant.
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..

This study evaluates chemotherapy regimens in carcinosarcoma, a cancer setting, with direct survival and toxicity outcomes.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Uterine Carcinosarcoma →

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Carboplatin1——1
Ifosfamide1——1
Paclitaxel1——1

Compounds with reported-positive results in Uterine Carcinosarcoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Carboplatin1 positive1 human
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
Cited positive studies (1)
Paclitaxel1 positive1 human
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
Cited positive studies (1)
Ifosfamide1 positive1 human
Limitations: Primary analysis was focused on uterine carcinosarcoma; ovarian carcinosarcoma results had limited precision.; The abstract reports noninferiority and superiority p-values but does not provide full confidence intervals for progression-free survival.; Toxicity details are summarized only briefly in the abstract..
Cited positive studies (1)

Evidence at a glance: compounds studied in Uterine Carcinosarcoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

CarboplatinHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Based on a single study.
IfosfamideHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Based on a single study.
PaclitaxelHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: median OS 37 mo, p P < .01 for noninferiority, P > .1 for superiority, n=449 PMID 35007153 · median-survival values 15–37 across 4 studies

Most authoritative study: Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Based on a single study.

Clinical trials in Uterine Carcinosarcoma

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →